Vanda Pharmaceuticals Receives First EU Orphan Designation for Imsidolimab in Generalized Pustular Psoriasis

Vanda Pharmaceuticals receives the first EU orphan designation for imsidolimab to treat rare, life-threatening GPP. FDA decision due Dec 12, 2026.